Literature DB >> 11093828

Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta.

E A Engels1, M D Sinclair, R J Biggar, D Whitby, P Ebbesen, J J Goedert, J L Gastwirth.   

Abstract

Human herpesvirus 8 (HHV-8) is thought to be highly prevalent in Mediterranean countries and sub-Saharan Africa, where it causes Kaposi's sarcoma in a small proportion of infected immunocompetent persons. However, the lack of serological tests with established accuracy has hindered our understanding of the prevalence, risk factors and natural history of HHV-8 infection. We tested 837 subjects from Congo, Botswana (mostly young adults) and Malta (elderly adults), using an immunofluorescence assay and 2 enzyme immunoassays (EIAs, to viral proteins K8.1 and orf65). Each assay found HHV-8 seroprevalence to be high (49-87%) in the African populations and generally lower (9-54%) in Malta. However, there was only modest agreement among tests regarding which subjects were seropositive (3-way kappa, 0.05-0.34). We used latent class analysis to model this lack of agreement, estimating each test's sensitivity and specificity and each population's HHV-8 prevalence. Using this approach, the K8.1 EIA had consistently high sensitivity (91-100%) and specificity (92-100%) across populations, suggesting that it might be useful for epidemiological studies. Compared with the K8.1 EIA, both the immunofluorescence assay and the orf65 EIA had more variable sensitivity (80-100% and 58-87%, respectively) and more variable specificity (57-100% and 48-85%, respectively). HHV-8 prevalence was 7% among elderly Maltese adults. Prevalence was much higher (82%) in Congo, consistent with very high Kaposi's sarcoma incidence there. Prevalence was also high in Botswana (87% in Sans, an indigenous group, and 76% in Bantus), though Kaposi's sarcoma is not common, suggesting that additional co-factors besides HHV-8 are needed for development of Kaposi's sarcoma. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093828     DOI: 10.1002/1097-0215(20001215)88:6<1003::aid-ijc26>3.0.co;2-9

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population‐based sample in Uganda.

Authors:  Benon Biryahwaho; Sheila C Dollard; Ruth M Pfeiffer; Fatma M Shebl; Stella Munuo; Minal M Amin; Wolfgang Hladik; Ruth Parsons; Sam M Mbulaiteye
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

2.  Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis.

Authors:  Maria Claudia Nascimento; Vanda Akico de Souza; Laura Masami Sumita; Wilton Freire; Fernando Munoz; Joseph Kim; Claudio S Pannuti; Philippe Mayaud
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

3.  Multifactorial etiology of Kaposi' sarcoma: a hypothesis.

Authors:  Harry W Haverkos
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

Review 4.  A Review of Human Herpesvirus 8, the Kaposi's Sarcoma-Associated Herpesvirus, in the Pediatric Population.

Authors:  Dorothy E Dow; Coleen K Cunningham; Ann M Buchanan
Journal:  J Pediatric Infect Dis Soc       Date:  2013-09-04       Impact factor: 3.164

5.  Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA.

Authors:  Georgina L Mbisa; Wendell Miley; Christine J Gamache; William K Gillette; Dominic Esposito; Ralph Hopkins; Michael P Busch; George B Schreiber; Richard F Little; Robert Yarchoan; Betty A Ortiz-Conde; Nazzarena Labò; Denise Whitby
Journal:  J Immunol Methods       Date:  2010-03-04       Impact factor: 2.303

6.  Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt".

Authors:  Sheila C Dollard; Lisa M Butler; Alison M Graves Jones; Jonathan H Mermin; Midion Chidzonga; Tsungai Chipato; Caroline H Shiboski; Christian Brander; Anisa Mosam; Photini Kiepiela; Wolfgang Hladik; Jeffrey N Martin
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

7.  Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China.

Authors:  T Zhang; N He; Y Ding; K Crabtree; V Minhas; C Wood
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

Review 8.  Kaposi sarcoma.

Authors:  Ethel Cesarman; Blossom Damania; Susan E Krown; Jeffrey Martin; Mark Bower; Denise Whitby
Journal:  Nat Rev Dis Primers       Date:  2019-01-31       Impact factor: 52.329

9.  Sensitivities and specificities of diagnostic tests and infection prevalence of Schistosoma haematobium estimated from data on adults in villages northwest of Accra, Ghana.

Authors:  Artemis Koukounari; Joanne P Webster; Christl A Donnelly; Bethany C Bray; Jean Naples; Kwabena Bosompem; Clive Shiff
Journal:  Am J Trop Med Hyg       Date:  2009-03       Impact factor: 2.345

10.  Development of whole-virus multiplex luminex-based serological assays for diagnosis of infections with kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 homologs in macaques.

Authors:  Jonathan T Ryan; Timothy M Rose
Journal:  Clin Vaccine Immunol       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.